NASDAQ · CRVO
Healthcare · Biotechnology
$2.56
Down-$0.03 (-1.17%)
Updated Sep 8, 2026, 4:34 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CRVO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CRVO.
CRVO research
Company profile and research snapshot.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 9, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Apr 7, 2026
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial designAdditional data from MRI analyses will also be featured at 2026
Benzinga · Mar 4, 2026
CervoMed Inc. (CervoMed or the Company) (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that it has successfully completed a Phase 1 healthy
Benzinga · Feb 18, 2026
Benzinga · Feb 18, 2026
D. Boral Capital analyst Jason Kolbert maintains CervoMed (NASDAQ:CRVO) with a Buy and maintains $31 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CRVO.
